ArticleCureus2026
Sequential Autologous Stem Cell Transplantation and Ciltacabtagene Autoleucel for Concurrent Multiple Myeloma and Presumptive Immunoglobulin Heavy- and Light-Chain Amyloidosis in a Patient With Systemic Lupus Erythematosus.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The co-occurrence of multiple myeloma (MM), systemic immunoglobulin light chain (AL) and heavy-and-light-chain (AHL) amyloidosis, and systemic lupus erythematosus (SLE) presents a highly complex therapeutic challenge. While B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapies have reshaped the treatment of MM, their safety and efficacy in patients with underlying autoimmune diatheses and severe organ-damaging amyloidosis remain sparsely documented. We report the case of a 67-year-old African American male with a history of SLE who presented with declining renal function and nephrotic-range proteinuria. A renal biopsy in month one revealed AL amyloidosis (Lambda type) with heavy chain (IgG1) co-deposition suggestive of AHL amyloidosis. A subsequent bone marrow biopsy confirmed concurrent MM. The patient was treated with induction chemotherapy (carfilzomib, daratumumab, lenalidomide), followed by an autologous stem cell transplant (ASCT) in month eight. He subsequently received ciltacabtagene autoleucel (cilta-cel) in month 14. By month 16, a bone marrow biopsy confirmed complete marrow remission. At his month 22 follow-up, the patient remained off all antineoplastic agents, demonstrating substantial organ response with near-complete resolution of proteinuria (9.4 mg/dL) and stabilized chronic kidney disease (CKD) stage 3b. Persistent, mild cytopenias and an elevated B-type natriuretic peptide (BNP) prompted ongoing post-CAR-T supportive care and evaluation for cardiac amyloidosis. This case highlights the feasibility of combining ASCT with BCMA-directed CAR T-cell therapy and its association with continued hematologic and renal improvement in highly complex patients with overlapping plasma cell dyscrasias, amyloid deposition, and autoimmune disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.